- Endo pharmaceuticals pennsylvania pdf#
- Endo pharmaceuticals pennsylvania update#
- Endo pharmaceuticals pennsylvania skin#
The most common cause of hypothalamic obesity was treatment of craniopharyngioma, followed by hypothalamic hamartoma, and juvenile pilocytic astrocytoma.
Endo pharmaceuticals pennsylvania skin#
The most commonly reported adverse events were nausea (69.2%), skin hyperpigmentation (38.5%), and vomiting (30.8%). All participants achieved a BMI reduction of at least 5%, while 10 of the 13 participants were able to achieve at least a 10% reduction.
Endo pharmaceuticals pennsylvania update#
We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.Most of this weight loss was achieved within the first 16 weeks of treatment, with an average BMI reduction of 16.8%. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results.
The forward-looking statements in this press release are qualified by these risk factors.
Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. and Qualitest Pharmaceuticals, please visit. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about the move, visit About EndoĮndo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments - branded pharmaceuticals, generics and devices and services. "I believe this move will undoubtedly send a positive message of growth, stability and promise to our pharmaceutical and business counterparts."Įndo is committed to a smooth and transparent transition for the Chadds Ford community that helped foster its transformation, and to Malvern, the new community that Endo believes will help sustain its ongoing growth. "This move is an important investment in Endo's future," says Dave Holveck, CEO of Endo Pharmaceuticals. With the acquisition of several healthcare, medical device and pharmaceutical companies over the last several years, Endo's new corporate headquarters addresses its continued growth, and will position Endo closer to the heart of the healthcare corridor in Pennsylvania, where nearly 100 other healthcare and life science companies currently reside. The move to a new corporate center, located approximately 18 miles from Chadds Ford, is part of Endo's long-term growth strategy and ongoing transformation into an all-around health solutions company. 31, 2011 /PRNewswire via COMTEX/ -Įndo Pharmaceuticals (Nasdaq: ENDP) today announced that it will relocate its corporate headquarters to a new facility based in Malvern, Pa., by December 2012.
Endo pharmaceuticals pennsylvania pdf#
PDF Version Pennsylvania-based Company Moves Its Headquarters to Support Ongoing Growth and ExpansionĬHADDS FORD, Pa., Oct.
0 kommentar(er)
